Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BCAL Diagnostics Limited (AU:BDX)
ASX:BDX
Holding AU:BDX?
Track your performance easily
BDX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.19
Previous CloseN/A
Volume98.04K
Average Volume (3M)298.39K
Market Cap
AU$34.77M
Enterprise ValueAU$27.07M
Total Cash (Recent Filing)$9.57M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Feb 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding365,967,900
10 Day Avg. Volume74,009
30 Day Avg. Volume298,395
Standard Deviation0.20
R-Squared0.00973
Alpha-0.00059
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BCAL Diagnostics Limited News
PremiumCompany Announcements
BCAL Diagnostics Issues Shares to Boost Growth
PremiumCompany Announcements
BCAL Diagnostics Issues New Performance Rights
PremiumCompany Announcements
BCAL Diagnostics Adjusts Capital Structure Amid Rights Lapse
PremiumCompany Announcements
Director Jayne Shaw Increases Stake in BCAL Diagnostics
PremiumCompany Announcements
BCAL Diagnostics to Issue 12 Million Unlisted OptionsPremiumCompany Announcements
BCAL Diagnostics Lists 3 Million Shares on ASX
PremiumCompany Announcements
BCAL Diagnostics Gains NATA Accreditation for Breast Cancer TestPremiumCompany Announcements
BCAL Diagnostics Secures Strong Support at AGMOptions Prices
Currently, No data available
---
Ownership Overview
BDX FAQ
What was BCAL Diagnostics Limited’s price range in the past 12 months?
BCAL Diagnostics Limited lowest share price was AU$0.09 and its highest was AU$0.18 in the past 12 months.
What is BCAL Diagnostics Limited’s market cap?
BCAL Diagnostics Limited’s market cap is AU$34.77M.
When is BCAL Diagnostics Limited’s upcoming earnings report date?
BCAL Diagnostics Limited’s upcoming earnings report date is Feb 19, 2025 which is in 31 days.
How were BCAL Diagnostics Limited’s earnings last quarter?
BCAL Diagnostics Limited released its earnings results on Aug 27, 2024. The company reported -AU$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.016.
Is BCAL Diagnostics Limited overvalued?
According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued.
Does BCAL Diagnostics Limited pay dividends?
BCAL Diagnostics Limited does not currently pay dividends.
What is BCAL Diagnostics Limited’s EPS estimate?
BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BCAL Diagnostics Limited have?
BCAL Diagnostics Limited has 365,967,900 shares outstanding.
What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?
BCAL Diagnostics Limited reported an EPS of -AU$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of BCAL Diagnostics Limited?
Currently, no hedge funds are holding shares in AU:BDX
---
BCAL Diagnostics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.00%
12-Months-Change
Fundamentals
Return on Equity
-92.74%
Trailing 12-Months
Asset Growth
46.52%
Trailing 12-Months
Company Description
BCAL Diagnostics Limited
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.
---
Technical Analysis
EBOS Group Limited
―
Integral Diagnostics Ltd.
―
Nanollose Ltd.
―
Anatara Lifesciences Ltd
―
Hexima Ltd
―
---